Read the full article below.
News
21/03/2025
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
Our news
News
08/11/2024
EMIH is a partner of the 8th edition of the Microbiota and Health Day organized by Lyonbiopôle Auvergne-Rhône-Alpes.
> READ
EMIH is a partner of the 8th edition of the Microbiota and Health Day organized by Lyonbiopôle Auvergne-Rhône-Alpes.
> READ
News
News
02/06/2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
> READ
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
> READ
> See all news